Inclusion Criteria:

- Positive HR or ER by immunohistochemistry

- Postmenopausal status at the time of treatment with fulvestrant

- Failure of at least one previous endocrine therapy before treatment with fulvestrant.

Exclusion Criteria:

- Patients who are still undergoing treatment with fulvestrant will not be eligible to
participate in the study